Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program

Author:

Gloeckler Ries Lynn A.1,Reichman Marsha E.1,Lewis Denise Riedel1,Hankey Benjamin F.1,Edwards Brenda K.1

Affiliation:

1. Surveillance Research Program, DCCPS, National Cancer Institute, Bethesda, Maryland, USA

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Describe the role and significance of the NCI Surveillance and End Results (SEER) Program. Discuss the evolving changes in cancer mortality statistics in the U.S. Explain some of the important definitions of population science as they relate to cancer. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com An overview of data on cancer at all sites combined and on selected, frequently occurring cancers is presented. Descriptive cancer statistics include average annual Surveillance, Epidemiology, and End Results (SEER) Program incidence, U.S. mortality and median age at diagnosis, and death for the period 1996–2000. Changes during the time period 1992–2000 are summarized by the annual percent change in SEER incidence and U.S. mortality data for this period. Five-year relative survival for selected cancers is examined by stage at diagnosis, based on data from 1990–1999. In addition, 5-year conditional survival for patients already surviving for 1–3 years after diagnosis is discussed as well as relative survival for other time periods. These measures may be more meaningful for clinical management and prognosis than 5-year relative survival from time of diagnosis. The likelihood of developing cancer during one's lifetime is 1 in 2 for males and 1 in 3 for females, based on 1998–2000 data. It is estimated that approximately 9.6 million people in the U.S. who have had a diagnosis of cancer are alive. Five-year relative survival varies greatly by cancer site and stage at diagnosis, and tends to increase with time since diagnosis. The median age at cancer diagnosis is 68 for men and 65 for women. The 5-year relative survival rate for persons diagnosed with cancer is 62.7%, with variation by cancer site and stage at diagnosis. For patients diagnosed with cancers of the prostate, female breast, corpus uteri, and urinary bladder, the relative survival rate at 8 years is over 75%.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference24 articles.

1. The surveillance, epidemiology, and end results program: a national resource;Hankey;Cancer Epidemiol Biomarkers Prev,1999

2. Cancer survival among US whites and minorities: a SEER (surveillance, epidemiology and end results) program population-based study;Clegg;Arch Intern Med,2002

Cited by 309 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3